| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5278 | Tyr(po(nme2)2 | Stable analog of phosphotyrosine (pTyr) |
|
| DCC5279 | Tyrosinase Inhibitor Thio-2 | Novel competitive inhibitor of tyrosinase enzyme |
|
| DCC5280 | U-101958 Maleate [224170-09-6] | Potent and selective dopamine D4 receptor antagonist |
|
| DCC5281 | Ua62784 | Novel potent inhibitor of microtubule polymerization, binding directly to tubulin α/β heterodimers via the colchicine-binding site, perturbing mitotic spindles, delaying cells in mitosis and promotes apoptosis |
|
| DCC5282 | Uawj172 | Novel potent and broad-spectrum antiviral agent against multiple strains of EV-D68, EV-A71, and CVB3, targeting the viral protein 2C |
|
| DCC5283 | Ubp512 | Selective modulator of NMDA_receptor>NMDA receptors, potentiates responses at GluN1/GluN2A |
|
| DCC5284 | Ubp618 | Novel pan-inhibitor of GluN1/GluN2 receptors |
|
| DCC5285 | Ubp646 | Novel pan potentiator of GluN1/GluN2 receptors |
|
| DCC5286 | Ubp684 | Novel NMDAR positive allosteric modulator (PAM), robustly potentiating responses at all GluN1/GluN2 subtypes and at neuronal NMDARs |
|
| DCC5287 | Ubtr008295a | Novel Antagonist of the USP5 Zinc Finger Ubiquitin-Binding Domain (USP5 ZnF-UBD) |
|
| DCC5288 | Ucb-11056 | Modulator of cyclic AMP generation, amplifing induced cyclic AMP formation in rat brain tissue; Nootropic |
|
| DCC5289 | ucb30889 | Potent ligand of synaptic vesicle protein 2A (SV2A) |
|
| DCC5290 | Ucb-6786 | Novel inhibitor of TNF signalling by stabilising an asymmetric form of the trimer, displaying a concentration-dependent response curve and selectivity over the TNFR1 extracellular domain and control proteins |
|
| DCC5291 | Ucb-6876 | Novel inhibitor of TNF signalling by stabilising an asymmetric form of the trimer, displaying a concentration-dependent response curve and selectivity over the TNFR1 extracellular domain and control proteins |
|
| DCC5292 | Ucb-fcrn-303 | Novel allosteric modulator of neonatal Fc receptor (FcRn), binding to the extracellular domain of FcRn |
|
| DCC5293 | uc-ddc-918013 | Selective competitive inhibitor of ATX-mediated hydrolysis of the lysophospholipase substrate FS-3 |
|
| DCC5294 | uc-ddc-931126 | Selective competitive inhibitor of ATX-mediated hydrolysis of the lysophospholipase substrate FS-3 |
|
| DCC5295 | uc-ddc-966791 | Competitive dual inhibitor of the hydrolysis FS-3 and the phosphodiesterase substrate p-nitrophenyl thymidine 5'-monophosphate |
|
| DCC5297 | Uck2-in-135546734 | Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors |
|
| DCC5298 | Uck2-in-135546812 | Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors |
|
| DCC5299 | Uck2-in-20874830 | Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors |
|
| DCC5300 | ucl-1972 | Histamine H3 Receptor Antagonist in Treatments of Cognition Disorders |
|
| DCC5301 | Ucl-2190 Hydrogen Maleate | The first potent nonimidazole H3 receptor antagonist (pKi=8.40) |
|
| DCC5302 | Ucm-05194 | Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), Showing Efficacy in Neuropathic Pain Amelioration |
|
| DCC5303 | Ucm-1336 | Novel potent isoprenylcysteine carboxylmethyltransferase (ICMT) inhibitor, improving survival in Ras-driven acute myeloid leukemia |
|
| DCC5304 | Ucm710 | Dual inhibitor of fatty acid amide hydrolase (FAAH) and α/β hydrolase domain 6 (ABHD6) |
|
| DCC5305 | Ucn-02 | Stereoisomer of UCN-01, inhibiting protein kinase C with a slightly reduced potency than UCN-01 |
|
| DCC5306 | Ucp1172 | Novel dual inhibitor of dihydrofolate reductase (DHFR) and its functional analog, Rv2671 |
|
| DCC5307 | Ucph-102f | Fluorescent excitatory amino acid transporter subtype 1 (EAAT1) selective inhibitor |
|
| DCC5308 | Ue2316 | Potent and selective 11ß-HSD1 inhibitor, improving memory, including after intracerebroventricular drug administration to the central nervous system alone |
|
